These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22044224)

  • 1. Lipophilic and amphiphilic interactions in glycoprotein 41: targets for therapy.
    Gochin M
    Curr Top Med Chem; 2011 Dec; 11(24):2945-6. PubMed ID: 22044224
    [No Abstract]   [Full Text] [Related]  

  • 2. Amphipathic properties of HIV-1 gp41 fusion inhibitors.
    Gochin M; Zhou G
    Curr Top Med Chem; 2011 Dec; 11(24):3022-32. PubMed ID: 22044226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of HIV-1 fusion inhibitors targeting gp41.
    Lu K; Asyifah MR; Shao F; Zhang D
    Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane-transferring regions of gp41 as targets for HIV-1 fusion inhibition and viral neutralization.
    Huarte N; Lorizate M; Pérez-Payá E; Nieva JL
    Curr Top Med Chem; 2011 Dec; 11(24):2985-96. PubMed ID: 22044227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
    Yi HA; Fochtman BC; Rizzo RC; Jacobs A
    Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.
    Lu L; Yu F; Cai L; Debnath AK; Jiang S
    Curr Top Med Chem; 2016; 16(10):1074-90. PubMed ID: 26324044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy.
    Garg H; Viard M; Jacobs A; Blumenthal R
    Curr Top Med Chem; 2011 Dec; 11(24):2947-58. PubMed ID: 22044225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41.
    Cai L; Jiang S
    ChemMedChem; 2010 Nov; 5(11):1813-24. PubMed ID: 20845360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
    Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
    FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
    Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
    ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting the sticky fingers of HIV-1.
    Blumenthal R; Dimitrov DS
    Cell; 2007 Apr; 129(2):243-5. PubMed ID: 17448985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.
    Chong H; Yao X; Qiu Z; Qin B; Han R; Waltersperger S; Wang M; Cui S; He Y
    J Biol Chem; 2012 Jun; 287(24):20281-9. PubMed ID: 22511760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Biological Evaluation of
    Meng G; Pu J; Li Y; Han A; Tian Y; Xu W; Zhang T; Li X; Lu L; Wang C; Jiang S; Liu K
    J Med Chem; 2019 Oct; 62(19):8773-8783. PubMed ID: 31513410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
    Melikyan GB; Egelhofer M; von Laer D
    J Virol; 2006 Apr; 80(7):3249-58. PubMed ID: 16537592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.
    Mostashari Rad T; Saghaie L; Fassihi A
    Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolved Proteins Inhibit Entry of Enfuvirtide-Resistant HIV-1.
    Ikeda T; Tennyson RL; Walker SN; Harris RS; McNaughton BR
    ACS Infect Dis; 2019 Apr; 5(4):634-640. PubMed ID: 30811933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
    Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
    Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Evaluation of Fluorination as Modification for Peptide-Based Fusion Inhibitors against HIV-1 Infection.
    Huhmann S; Nyakatura EK; Rohrhofer A; Moschner J; Schmidt B; Eichler J; Roth C; Koksch B
    Chembiochem; 2021 Dec; 22(24):3443-3451. PubMed ID: 34605595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.